DDI Study Between Dorzagliatin and Rifampicin

Hua Medicine Limited15 enrolled

Overview

The purpose of this drug-drug interaction study is to investigate the impact of rifampicin on the pharmacokinetics of Dorzagliatin.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Drug Interaction

Interventions

DorzagliatinDRUG

GKA currently under clinical development

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Body weight ≥ 50 kg (male) or ≥ 45 kg (female) * BMI within 19～26 kg/m2 Exclusion Criteria: * History or disease status that may impact the ADME of the study * Use of any drugs, OTCs, or hebal within 4 weeks of screening * Drug abuse * Blood donation

Locations (1)

Central Hospital of Xuhui District

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Cmax

Peak plasma concentration

Time frame: up to 96 hours

AUClast

Area under the plasma concentration curve

Time frame: up to 96 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.